Radiotherapy for elder patients aged ≥80 with clinically localized prostate cancer – Brachytherapy enhanced late GU toxicity especially in elderly

[1]  M. Agudelo-Botero,et al.  Epidemiology, progression, and predictive factors of urinary incontinence in older community‐dwelling Mexican adults: Longitudinal data from the Mexican Health and Aging Study , 2019, Neurourology and urodynamics.

[2]  Y. Yoshioka,et al.  Radiotherapy for Elderly Patients Aged ≥75 Years with Clinically Localized Prostate Cancer—Is There a Role of Brachytherapy? , 2018, Journal of clinical medicine.

[3]  A. Jemal,et al.  Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries , 2018, CA: a cancer journal for clinicians.

[4]  D. Dearnaley,et al.  The Efficacy and Safety of Conventional and Hypofractionated High-Dose Radiation Therapy for Prostate Cancer in an Elderly Population: A Subgroup Analysis of the CHHiP Trial. , 2018, International journal of radiation oncology, biology, physics.

[5]  L. Holmberg,et al.  Age at diagnosis and prostate cancer treatment and prognosis: a population-based cohort study , 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

[6]  M. Aapro,et al.  Management of Prostate Cancer in Elderly Patients: Recommendations of a Task Force of the International Society of Geriatric Oncology. , 2017, European urology.

[7]  H. Yamazaki,et al.  Long-term Tumor Control and Late Toxicity in Patients with Prostate Cancer Receiving Hypofractionated (2.2 Gy) Soft-tissue-matched Image-guided Intensity-modulated Radiotherapy. , 2017, Anticancer research.

[8]  S. Kariya,et al.  Nationwide multi-institutional retrospective analysis of high-dose-rate brachytherapy combined with external beam radiotherapy for localized prostate cancer: An Asian Prostate HDR-BT Consortium. , 2017, Brachytherapy.

[9]  P. Grosclaude,et al.  Current impact of age and comorbidity assessment on prostate cancer treatment choice and over/undertreatment risk , 2017, World Journal of Urology.

[10]  David Gillatt,et al.  10-Year Outcomes after Monitoring, Surgery, or Radiotherapy for Localized Prostate Cancer. , 2017, The New England journal of medicine.

[11]  S. K. Van Den Eeden,et al.  Treatment Preferences for Active Surveillance versus Active Treatment among Men with Low-Risk Prostate Cancer , 2016, Cancer Epidemiology, Biomarkers & Prevention.

[12]  R. DiPaola,et al.  Fifteen-year Outcomes Following Conservative Management Among Men Aged 65 Years or Older with Localized Prostate Cancer. , 2015, European urology.

[13]  S. Naito,et al.  Current use of active surveillance for localized prostate cancer: A nationwide survey in Japan , 2015, International journal of urology : official journal of the Japanese Urological Association.

[14]  T. Miki,et al.  Assessment of permanent brachytherapy combined with androgen deprivation therapy in an intermediate‐risk prostate cancer group without a Gleason score of 4 + 3: A single Japanese institutional experience , 2014, International journal of urology : official journal of the Japanese Urological Association.

[15]  B. Davison,et al.  Factors influencing treatment decision making and information preferences of prostate cancer patients on active surveillance. , 2012, Patient education and counseling.

[16]  M. Gorin,et al.  Factors that influence patient enrollment in active surveillance for low-risk prostate cancer. , 2011, Urology.

[17]  Srinivasan Vijayakumar,et al.  Analysis of influence of age on acute and chronic radiotherapy toxicity in treatment of prostate cancer. , 2005, Urology.

[18]  J. Stanford,et al.  Health outcomes after external-beam radiation therapy for clinically localized prostate cancer: results from the Prostate Cancer Outcomes Study. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.